Dipeptidyl peptidase 4 inhibitor‐associated mucous membrane pemphigoid

Suezawa, Mei; Dainichi, Teruki; Kaku, Yo; Izumi, Maiko; Kataoka, Koki; Ishii, Norito; Koga, Hiroshi; Izumi, Kiyotaka; Nishie, Wataru

doi:10.1111/1346-8138.16061

Cited by 9 publications

(10 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MMP and BP both share the same immunity and are differentiated by clinical features such as more frequent mucous membrane lesions and scarring lesions in MMP. To the best of our knowledge, two cases of MMP induced by DPP-4 inhibitors have been reported, but no cases of gliptin-induced LABD could be found in the literature [ 12 , 14 ]. Vildagliptin seems to be the most probable gliptin to induce BP among DPP-4 inhibitors.…”

Section: Discussionmentioning

confidence: 99%

“…Autoantibodies mainly target the NC16a domain of BP180 in conventional BP. However, in BP and its subtypes that are induced by DPP-4 inhibitors, it is different, and autoantibodies also work against other domains of BP (e.g., LAD1) [ 14 , 15 ].…”

Section: Discussionmentioning

confidence: 99%

“…The first case report of the association between gliptins and the occurrence of BP was diagnosed in 2011 by Skandalis et al [ 13 ]. Recently, few articles have been published about the impact of DPP-4 inhibitors on rare variants of BP such as mucous membrane pemphigoid (MMP, cicatricial pemphigoid) and pemphigoid nodularis [ 12 , 14 , 15 ]. This case series aimed to report a possible association of rare forms of BP: MMP, pemphigoid nodularis, and linear IgA bullous dermatosis (LABD), with gliptins use.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients

et al. 2022

View full text Add to dashboard Cite

Bullous pemphigoid is the most common acquired bullous disease with an autoimmune basis and a tendency to involve mostly old people. By rising incidence of diabetes all over the world, consumption of antidiabetes medications has also increased. One of the most used antidiabetes drugs is gliptin family (dipeptidyl-peptidase 4 inhibitor). Recently, this class of oral antidiabetic agents showed a correlation with the occurrence of bullous pemphigoid and its subtypes, including mucous membrane pemphigoid and pemphigoid nodularis. We are reporting a case series of 4 diabetes patients that we diagnosed with bullous pemphigoid subtypes (mucous membrane pemphigoid, pemphigoid nodularis, and its rarest subtype, linear IgA bullous dermatosis) after taking different drugs of gliptin family.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The first cases of BP associated with DPP4is were reported in 2011, since then evidence supporting their association has increased [3,4,14,15,[25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42]. Although the pathophysiology is not fully yet understood, it is hypothesized that DPP4 is modify the immune response and/or alter the antigenic properties of the epidermal basement membrane resulting in bullous pemphigoid [43].…”

Section: Case Descriptionmentioning

confidence: 99%

Bullous Pemphigoid in Older Adults Treated with DPP4i: A Case Series

Katia¹,

Álvarez‐Cisneros²,

Ana³

2023

J Geriatr Med Gerontol

View full text Add to dashboard Cite

Bullous pemphigoid (BP) is a rare autoimmune subepithelial blistering disease affecting mostly older adults [1]. Studies have calculated an annual incidence ranging from 2.4% to 21.7% per million population. While triggers are found in less than 15% of cases [2,3], drugs are well-known trigger factors. Recently, dipeptidyl peptidase-4 inhibitors (DPP4i) have been associated to this condition [4]. Our study presents four cases of older adults with BP associated to the use of DPP4i. The relevance of this study is to emphasize the association between these drugs and BP in older adults where polypharmacy is frequent.

show abstract

“…In addition, the DPP-4i would decrease chemotaxis and T cell immunity that might trigger the autoimmune disease occurrence [ 49 ]. Nonetheless, we should be aware of the potential risk of DPP-4 inhibitors causing autoimmune diseases such as RA or bullous pemphigoid because there are case reports or incidents as mentioned above [ 51 , 52 , 53 ].…”

Section: Diabetes and Autoimmunity: Is There A Link Through Dpp-4?mentioning

confidence: 99%

Glucose as a Potential Key to Fuel Inflammation in Rheumatoid Arthritis

Masuko

2022

Nutrients

View full text Add to dashboard Cite

Glucose is the most important source of energy and homeostasis. Recent investigations are clarifying that glucose metabolism might be altered in rheumatoid arthritis (RA), which would play a role in the inflammatory phenotype of rheumatoid synovial fibroblasts. It may also play a role in a variety of autoimmune diseases’ pathophysiology by modulating immune responses and modifying autoantigen expressions. The research into glucose and its metabolism could lead to a better understanding of how carbohydrates contribute to the occurrence and duration of RA and other autoimmune diseases.

show abstract

Dipeptidyl peptidase 4 inhibitor‐associated mucous membrane pemphigoid

Cited by 9 publications

References 7 publications

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients

Bullous Pemphigoid in Older Adults Treated with DPP4i: A Case Series

Glucose as a Potential Key to Fuel Inflammation in Rheumatoid Arthritis

Contact Info

Product

Resources

About